Introduction
Neuroblastoma is the most common solid tumor diagnosed in the first year of life. It is characterized by a remarkably diverse clinical behavior ranging from spontaneous regression or maturation to malignant disease. This diversity is mainly due to the complex biology and genetics of the tumor itself. structural ones, neuroblastomas with unfavorable clinical outcome are commonly characterized by segmental chromosomal aberrations and MYCN amplifications (MNAs). 1, 3, 4 Deep-sequencing studies have provided additional insights into the genomic landscape of the tumor, revealing that chromothripsis, as well as mutations and deletions of particular genes are associated with high-risk disease at various frequencies. 5, 6 In addition, efforts have been made to improve our understanding of the transcriptomic landscape of neuroblastomas. These studies mainly analyzed the prognostic value of gene expression-based classifiers for neuroblastoma, concluding an improved clinical endpoint prediction. [7] [8] [9] Although all these genomic and transcriptomic studies have advanced our understanding of the disease, they have mainly focused on primary tumors. However, a common feature in neuroblastoma is the presence of disseminated tumor cells (DTCs) in the bone marrow (BM) of metastatic (M) stage patients. More than 90% of stage M patients present with DTC infiltration in the BM at diagnosis. 10 Detection of DTCs in the BM of patients who are older than 18 months is of high prognostic importance, as these patients frequently suffer from disease recurrence and poor outcome. 11 Importantly, BM can be used for the molecular quantification of minimal residual disease (MRD) and outcome prediction. 12 In our recent studies, we have shown that BM-derived DTCs are suitable for genomic and transcriptomic analyses. 13, 14 Furthermore, it has been demonstrated that DTCs can be highly informative regarding the identification of the relapse-seeding clone. 15 However, little is known about gene expression changes occurring in DTCs upon dissemination and tumor progression. So far, only a single group has performed gene expression profiling of BM-derived DTCs from 11 neuroblastoma patients by microarray analysis. In this study, Morandi et al. mainly focused on the identification of genes differentially expressed between diagnostic DTCs and primary tumors to identify genes which could serve as prognostic markers for high-risk neuroblastoma patients. 16 With our study, we aim to shed more light on the transcriptomic landscape of DTCs, which are frequently considered to lead to relapse in various cancers. 17 To our knowledge, we present the first RNA-Seq study of disseminated neuroblastoma cells in which their expression profile was characterized by sequencing the mRNA and comparing the expression profiles of primary tumors, BM-derived DTCs and the corresponding BMderived mononuclear cells (MNCs). Our findings may stimulate further functional research projects to decipher the DTCs that frequently cause relapse in neuroblastoma patients.
Materials and Methods

Overview of patient samples
Primary tumor (n 5 16), DTC (n 5 42), and corresponding MNC (n 5 28) samples of 53 stage M neuroblastoma patients were sequenced and analyzed. For three patients (n 5 3), matching DTC and tumor samples were available at diagnosis. For five patients (n 5 5), matching diagnostic and relapse DTCs were available. One DTC sample was sequenced twice, before enrichment (D07r2) and after enrichment (D07r). An overview of patients and samples is shown in Figure 1 and the Supporting Information Table S1 . RNA-Seq data are available on the gene expression omnibus (GEO) repository (accession number GSE94035). This study was approved by the St. Anna Kinderspital Ethics Commission in Vienna, Austria.
Sample preparation for RNA-seq
The primary tumor and BM samples were stored in liquid nitrogen. Cryosection slides of tumors were prepared and H&E stainings were performed. Identified tumor cells-rich regions were cut out from the respective tumor pieces and homogenized in QIAzol (Qiagen) with the gentleMACS Dissociator (Miltenyi). The dimethyl sulfoxide (DMSO) frozen MNC fraction of BM aspirates was thawed and density gradient centrifugation (LymphoprepTM, AXIS-SHIELD PoC AS) was performed. Following the density gradient centrifugation, DTCs were labeled and enriched at 48C as described earlier. 13 In brief, the MNC fraction containing DTCs was collected after density gradient separation and washed with phosphatebuffered saline (PBS) at 300g for 10 min at 48C. The supernatant was discarded and the cells were resuspended in 2 ml ice-cold magnetic-activated cell sorting (MACS) buffer (PBS pH 7.2, 0.5% bovine serum albumin, 2 mM ethylene diamine tetraacetic acid). Thereafter, the cell suspension was incubated at 48C for 20 min with 2.5 ml of FITC-labeled anti-GD2 antibodies (14.18 delta CH2 clone), followed by a 15-min incubation with 75 ml anti-FITC magnetic beads (Miltenyi) at 48C. The MACS sorting was continued at 48C and the enriched DTC fraction and the corresponding tumor cellsdepleted MNC fraction were separately collected and homogenized in QIAzol. was used to call differentially expressed genes (nbinomWaldTest, minReplicates 5 5, cooksCutoff 5 0.7, trim 5 0.4). In addition, we used DESeq2 to generate a normalized (function "fpm", robust 5 TRUE) and variance-stabilized (function "vst") gene expression matrix for import into and further analysis in Qlucore v3.2. All samples used in this study passed internal quality control (QC) checks, including base qualities, mapping rates, duplication rates, and 5 0 -3 0 coverage, which were performed on the basis of FastQC and RSeQC reports. 21 Gene set enrichment analysis (GSEA) was performed with the xtools.gsea.GseaPreranked module implemented in Broad's javaGSEA stand-alone desktop application (v2.0.13). 22, 23 Gene sets for GSEA were downloaded from MSigDB 5.0. 22 Input genes were ranked by DESeq2 p values from most to least significant, considering the directionality of change. False discovery rates were empirically assessed by permutation analysis with 1,000 iterations. GSEA command line options included "-collapse false -mode Max_probe -norm meandiv -scoring_ scheme weighted -include_only_symbols true -make_sets true -rnd_seed 149 -gui false -nperm 1000 -set_max 5000 -set_ min 5" (all other options default). The complete RNA-Seq analysis pipeline (including alignment, QC, differential gene expression analysis, and GSEA) was implemented and run on the workflow management platform Anduril (http://www.anduril.org). 24 
Positional enrichment of differentially expressed genes
To find chromosomal regions enriched for differentially expressed genes, we used the Perl script "pge.pl" provided by De Preter et al. 25 This method implements a hypergeometric test to test for significant co-localization of a given query gene set among a given background (or reference) gene set. In Figure 6 , the query gene set comprised all genes significantly differentially expressed between diagnosis and relapse DTC samples (q 0.2, |log2FC| 0.5) and the background gene set contained all genes from Ensembl GCRh37 build 75 except rRNA genes.
Sample preparation and DNA extraction for qPCR DNA was extracted from samples of 10 patients (n 5 10) with the high salt extraction method. For four patients (n 5 4), the DNA was extracted from the primary tumor, the BM-derived DTCs and a tumor cell-free BM or peripheral blood sample. For another four patients (n 5 4), the DNA was extracted from the primary tumor and the BM-derived DTCs. For the remaining two patients (n 5 2), the DNA was extracted from DTCs and tumor cells-free BM.
Real-time qPCR
For each quantitative polymerase chain reaction (qPCR) reaction, 6.25 ng DNA was used, and for each sample, three technical replicates were performed. Primers for the nuclear ALB gene (located on chromosome 4) and for a 344-bp fragment of the mitochondrial genome (nucleotides m.8151-8494), encompassing the MT-TK gene were used: ALB exon 12 (GenBank NM_000477 
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Genomic copy-number analysis
For 34 enriched DTCs, we used one aliquot of the samples for genome analysis that was performed earlier. 13, 15 The data were analyzed with the ChAS software (Affymetrix). SNP array data analyzed for these studies are available on the GEO repository under the accession number GSE84291, and the corresponding GEO identifier can be found in the Supporting Information Table S3 .
Results
Magnetic bead-based enrichment led to a three-fold increase in DTC purity
DTCs are usually underrepresented in the BM, which necessitates their enrichment before gene expression analysis. The median infiltration of GD2 POS tumor cells in the BM aspirates (n 5 42) was determined by immunofluorescence (IF) microscopy to be 20% before enrichment (range 1%-80%) and 65% (range 19%-96%) after magnetic bead-based enrichment (Fig. 2a) . The DTC content after enrichment was sample-dependent ( Fig. 2b) with 27% of samples containing <50% DTCs, 37% of samples containing 50%-75% DTCs, and 37% of samples with >75% DTCs after enrichment. Overall, enrichment resulted in a threefold increase in tumor cell content within DTC samples. Negative fractions (MNCs) were examined by IF (Fig. 2c ) and all samples with detectable GD2 POS DTCs were excluded from further analysis.
Gene expression signature dominated by cell type and MYCN expression
We expected differences in global gene expression patterns to be largely driven by cell type (for convenience we label tumor, DTC and MNC samples as distinct cell types in this article). Indeed, principal component analysis of all genes transcribed in tumors and MNCs unambiguously separated samples by cell type along the first principal component (x-axis), with tumor samples (16 diagnostic samples) clustering to the right and MNC samples (n 5 28: 14 diagnostic samples and 14 relapse samples) to the left (Fig. 3a) . In-between these two clusters and along the same axis, DTCs (n 5 42: 22 diagnostic and 20 relapse samples) scattered according to their tumor cell content. MYCN expression status explained most of the remaining gene expression variability in tumor and DTC samples (second principal component, y-axis) (Fig. 3b) , revealing a strong effect of MYCN upregulation on the global gene expression of tumors (n 5 6 with MYCN-low and n 5 10 with MYCN-high) and DTCs (n 5 26 with MYCN-low and n 5 16 with MYCN-high). GSEA for DTC MYCN-high and MYCNlow samples revealed several previously described MYCN-associated gene sets (Supporting Information Table S4 ), including a gene set containing genes coregulated with MYCN upregulation in primary neuroblastomas 26 ( Fig. 3c) . Furthermore, unsupervised clustering with the top-100 differentially expressed genes between MYCN-high and MYCN-low DTC samples (Supporting Information Table S5 ) separated tumors and DTCs by MYCN expression rather than cell type or tumor cell (Fig. 3d) . Seventy six genes were upregulated in DTC MYCN-high samples, with MYCN itself being the most significantly upregulated gene (q 5 3.7 3 10 251 , log 2 FC 5 4.9). Except for one case (D04d, sample with 82% tumor cells), MYCN expression levels were in line with the MNA status as determined by fluorescence in situ hybridization (FISH) and/or SNP array (Supplementary Information Table S1 , with additional information for D04d). D04d and the matching tumor sample contained approximately 25-30 copies of MYCN as determined by SNP array (Supporting Information Fig. S2) . Unfortunately, no expression information on the corresponding tumor was available due to degraded RNA in this sample. The remaining 24 genes were downregulated in the DTC MYCNhigh samples. Although not among the top-100 regulated genes, MYC was downregulated in DTC MYCN-high samples (q 5 0.006, log 2 FC 5 1). 
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Candidate markers for MRD diagnosis in stage M neuroblastoma patients
The identification of robust MRD markers is a crucial step in the exact diagnosis of tumor cells in the BM. By comparing the gene expression of DTCs (n 5 42) and MNCs (n 5 28), we found that eight markers for MRD diagnosis in neuroblastoma proposed by Cheung et al. 27 were upregulated in tumor and DTC samples, and only marginally or not at all transcribed in the corresponding MNC samples (Fig. 4a) . Among these eight genes, PHOX2B was the most significantly upregulated gene in our data set (q 5 3 3 10
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, log 2 FC 5 8.7). Noteworthy, in one DTC sample (D27d), PHOX2B was not transcribed. GABRB3, CRMP1, KIF1A, CCND1, TACC2, ISL1 and DDC were all significantly upregulated in DTCs as compared to MNCs (q < 8.5 3 10 274 , log 2 FC > 6). However, it is notable that CCND1 was also transcribed by non-tumor cells of the BM. Furthermore, we found a higher variation in the DDC expression among tumor and DTC samples as compared to the other genes. This variance was associated with MYCN expression as DDC was downregulated in DTC MYCN-high (n 5 16) samples as compared to MYCN-low samples (n 5 26) (q 5 0.03, log 2 FC 5 1). In addition to the eight published genes, we identified 224 genes that were significantly upregulated in DTCs as compared to corresponding MNCs (q < 8 3 10 275 log 2 FC > 6) (Supporting Information Table S6 ). The eight most significantly upregulated genes (q < 1 3 10 2232 ) were ELAVL3, MAST1, SCG3, MAP1B, MAPK8IP2, DPYSL5, REEP2 and SOX11 (Fig. 4b) . The differential expression between DTCs and MNCs of the top seven identified genes was more significant (q < 1.3 3 10 2243 ) than the differential expression of PHOX2B (q 5 3 3 10 2234 ).
DTCs overexpress genes encoded by mitochondrial DNA
The tumor microenvironment is of critical importance for dissemination, arrest and progression of DTCs, and therefore, we were keen to characterize the DTCs which were infiltrating the BM. We compared the expression signature of tumors (total number 5 16: 10 with MYCN-high and 6 with MYCN-low) to DTCs (total 
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Rifatbegovic et al. number 5 42: 16 with MYCN-high and 26 with MYCN-low) in a non-paired manner and found that the expression levels of neuroblastoma hallmark genes MYCN and PHOX2B were retained in DTCs. However, we identified 322 genes with an altered gene expression (q < 0.001, |log 2 FC|>2). We confirmed our observations by comparing the tumor samples with a subset of highly enriched DTC samples (tumor cells > 90%, n 5 3, Supporting Information Table S7 ). Among the top differentially expressed genes between tumor and DTC samples (Fig. 5a) , we found genes involved in metastasis initiation and angiogenesis, for example, MGP, BGN, POSTN and ANGPT2, to be upregulated in tumors. The differentially expressed genes were enriched in several gene sets (Supporting Information Table S8 ) including the Hallmark Angiogenesis gene set (Fig. 5b ) and other gene sets containing genes involved in metastasis initiation. When comparing the gene expression signature of DTC and tumor samples under consideration of the MYCN expression level (Supporting Information  Table S9 ), the expression profile largely resembled the above mentioned gene sets.
Interestingly, transcript levels of genes encoded by the mtDNA were found to be significantly higher in DTCs as compared to the analyzed tumors and MNCs (Figs. 5a, 5c and 5d). In a cohort of eight patients, we performed qPCR experiments to quantify the mtDNA levels. In six of these eight patients, the quantity of mtDNA was significantly higher in the DTC samples as compared to the matching tumors ( Fig. 5e ; Supporting Information Table S10 ). However, genes encoded by the nuclear DNA (nDNA), which are essential for mitochondrial function such as the oxidative phosphorylation (OXPHOS) and which are part of the same protein complexes as those encoded by the mtDNA, were not upregulated in DTCs (Supporting Information Fig. S3 ).
Relapse DTCs downregulate genes on chromosome 19
By comparing the gene expression signature of diagnostic (total number 5 22: 10 with MYCN-high and 12 with MYCN-low) and relapse DTCs (total number 5 20: 6 with MYCN-high and 14 with MYCN-low) in a non-paired manner, we found the gene expression to be fairly stable over time, with only 113 differentially expressed genes under relaxed cut-offs (q < 0.01, |log 2 FC| > 0.5; Fig. 6a ; Supporting Information Table S11 ). Interestingly, among the downregulated genes in relapse DTCs, we found a strong positional enrichment on chromosome 19 (31 of 113 genes; positional enrichment q value 5 9 3 10
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; Fig. 6b) . Notably, we identified five tumor suppressors among the 31 downregulated genes; STK11, SIRT6, CADM4, BBC3 (also known as PUMA) and GLTSCR2. Genomic analysis of 34 DTC samples revealed clonal deletions affecting a portion of the 31 downregulated genes encoded by chromosome 19. Although these deletions occurred at higher frequency in relapse patients (9 of 17 samples) as compared to the diagnostic samples (4 of 17 samples), the positional distribution of downregulated and deleted genes did not coincide. While chromosomal aberrations in relapse samples were mainly found on 19q (8 of 20 samples), most of the downregulated genes were encoded by 19p ( Fig. 6b ; Supporting Information Table S3 ) which rarely contained deletions (3 of 20 samples). The three tumor suppressor genes encoded by 19q (CADM4, BBC3/PUMA and GLTSCR2) were more frequently deleted in relapse DTCs (29%) as compared to the diagnostic DTCs (12%), whereas the two tumor suppressor genes encoded by 19p were deleted at lower frequencies. By correlating the gene expression of the identified tumor suppressor genes with the overall survival and event free survival (EFS) in publically available datasets 5, [28] [29] [30] (R2: Genomics Analysis and Visualization
Platform http://r2.amc.nl), we found low expression levels of CADM4 and BBC3/PUMA to correlate with worse EFS (Supporting Information Fig. S4 ; Table S12 ).
Discussion
BM is a frequent homing organ for DTCs of various cancer types. It can serve as a metastatic niche for DTCs, which finally can cause disease recurrence after treatment. 31 Thus, the presence of DTCs is considered as an important prognostic marker for poor outcome in various cancer types, such as breast cancer, 32 Ewing sarcoma, 33 and neuroblastoma-with the exception of stage MS tumors which frequently show a minor BM involvement despite mostly favorable disease outcome. 3, 34 Therefore, the characterization of DTCs may help to improve our knowledge about treatment failure and disease relapse. We searched for expression changes occurring during the course of disease by analyzing the gene expression profiles of diagnostic and relapse DTCs. Unexpectedly, the transcriptional landscape of diagnostic DTCs resembled that of relapse DTCs to a large extent, although these patients had experienced multimodal treatment. This observation may be explained by the protective BM niche, just as it has been shown that the BM microenvironment promotes their survival, dormancy, growth and drug resistance. 35 Remarkably, we found that the genes which were differentially expressed between diagnostic and relapse DTCs show a positional enrichment on chromosome 19, with five tumor suppressor genes being downregulated in relapse DTCs. Although chromosome 19 deletions are only rarely observed in neuroblastoma, 36 several studies reported deletions or copy neutral loss of heterozygosity (cnLOH) in primary tumors at low frequency. 37, 38 Interestingly, our recent study revealed a higher frequency of partial chromosome 19 deletions in DTCs of relapse patients as compared to diagnostic DTCs. 15 Although most reported chromosome 19 deletions in our and other studies affected the q-arm, we found most of the differentially expressed genes to be encoded by the p-arm. While the downregulation of genes located on the q-arm can be explained, at least partially, by deletions of the particular genes, the rare gene deletions in the p-arm suggest other, trans-regulatory mechanisms of gene expression. 1 Thus, epigenetic studies focusing on DTCs seem reasonable and could
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shed more light on the transcriptomic alterations occurring in these cells. Chromosome 19 encodes several well described tumor suppressor genes whose downregulation is associated with progression in various cancers. We identified five of these tumor suppressor genes to be downregulated in relapse DTCs. BBC3/PUMA is a critical apoptosis inducer whose expression ablation is oncogenic and can lead to therapeutic resistance. 39 A recent study demonstrated that BBC3/PUMA is the critical determinant of the therapeutic response to p53 activation and subsequent apoptosis induced by Nutlin3a, a cancer therapeutics that is in clinical trial. 40 A screening study with flubendazole, another compound that exerts anticancer activity, identified neuroblastoma as a potential flubendazole-sensitive cancer entity. The flubendazole efficacy was increased by nutlin-3, but the flubendazole-induced antineuroblastoma effect was significantly impaired upon BBC3/ PUMA depletion in the analyzed neuroblastoma cell lines.
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SIRT6 is another tumor suppressor that we found to be downregulated in relapse DTCs and whose loss was associated with poor outcome in several cancers. 42 Analysis of data from the Cancer Genome Atlas database revealed that SIRT6 was deleted in 20% of analyzed cancers. 43 The loss and/or downregulation of the remaining three suppressor genes in DTCs of relapse samples, namely STK11, CADM4 and GLTSCR2, was also reported to be associated with tumor progression in various cancers. Thus, we assume that the downregulation of the five tumor suppressor genes encoded by chromosome 19 in relapse DTCs represents a possible survival advantage for DTCs.
Furthermore, we found that genes involved in metastasis initiation and angiogenesis were upregulated in the primary tumors in contrast to DTCs and MNCs, which reside in the highly vascularized BM. 44 Besides the downregulation of these genes, DTCs were particularly characterized by an increased amount of mtDNA and the corresponding transcripts that are encoded by this small genome. Notably, also BM-derived MNCs had elevated levels of mtDNA transcripts as compared to primary tumors, although significantly less than BM-derived DTCs. A numerical increase in mitochondria is a characteristic feature of various cancers, and it is well known that mitochondria impart considerable flexibility for cancer cells in harsh environments, such as hypoxic BM. 45 However, the elevated level of transcripts encoded by mtDNA in DTCs is rather surprising, as these genes code only for a minority of subunits that are necessary for functional mitochondria. The vast majority of subunits, for example, for the OXPHOS complex, is encoded by the nDNA. However, unexpectedly, these genes were not upregulated in DTCs. A possible explanation for this phenomenon is the uptake of functional mitochondria by tumor cells from the BM microenvironment. 46, 47 However, functional studies will be necessary to understand the exact mechanism and causes for elevated mtDNA and increased levels of transcripts encoded by it. Apart from these and other differences, DTCs also retained oncogenic features of the tumor. Particularly, the transcription of MYCN was comparable in tumor and DTC samples, as well as the transcription of MYC, which was earlier shown to be anti-correlated with MYCN in neuroblastoma. 48 As the BM is a common homing organ for disseminated neuroblastoma cells, it is widely used for MRD testing during or after cytotoxic treatment. 34 Besides the standardized immunocytological detection of MRD, 10 real-time quantitative polymerase chain reaction approaches are also used for MRD detection. 12 Our three-fold enrichment of BM-derived DTCs and their separation from the corresponding BMderived MNCs enabled us to characterize their gene expression profiles and to extend the variety of potential marker for MRD detection in stage M neuroblastoma. Our data indicate that the detection of one or two MRD markers can lead to unreliable results, as the expression of tumor-specific genes varies between samples and, moreover, a number of genes can also be expressed by non-tumor cells of the BM. Finally, not all supposed NB-specific markers are expressed by all DTCs, as we could, for example, show for PHOX2B, the widely used MRD marker in neuroblastoma. Thus, it is necessary to consider testing and applying MRD marker panels as suggested by Stutterheim et al.. 49 For this purpose, for example, 2 to 3 of the 224 most highly and specifically expressed genes in BM-derived DTCs might be considered for the design of highly specific and sensitive MRD detection markers. Furthermore, feature selection methods 50 could be applied to our data to determine a minimal discriminant subset of genes being sufficient to classify presence versus absence of DTCs in the BM, serving as the basis to create a diagnostic test with a predefined sensitivity and specificity.
In conclusion, our study demonstrated that disseminated neuroblastoma cells retain some of their tumor's oncogenic features, but in addition undergo transcriptomic changes upon dissemination and cancer progression, particularly, the downregulation of tumor suppressor genes encoded by chromosome 19. These insights can stimulate further functional, and especially epigenetic, studies to decipher those cells that are assumed to be the main cause for treatment failure and disease relapse in high-risk neuroblastoma patients.
